Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$22.40 USD
-0.14 (-0.62%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $22.46 +0.06 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Cullinan Therapeutics, Inc. [CGEM]
Reports for Purchase
Showing records 41 - 49 ( 49 total )
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; CLN-081 Clinical and Regulatory Updates Expected in 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impressive CLN-081 Data at ASCO; Raising Price Target to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Interim CLN-081 Data in ASCO Abstract for NSCLC Patients With EGFR Exon 20 Mutations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; CLN-081 Update Expected at ASCO; Two IND Filings Projected for 2021 With Two More in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results; More CLN-081 Data Expected Mid-2021; Raising PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficiently Building a Diverse Pipeline; Initiating With a Buy Rating and $47 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department